Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial

To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear supplements in managing dry eye disease (DED). Ninety-nine participants fulfilling the TFOS DEWS II diagnostic criteria for DED (64% females; mean ± SD age, 44 ± 16 years) were enrolled in a prospective, multic...

Full description

Saved in:
Bibliographic Details
Published in:The ocular surface 2021-04, Vol.20, p.62-69
Main Authors: Craig, Jennifer P., Muntz, Alex, Wang, Michael T.M., Luensmann, Doerte, Tan, Jacqueline, Trave Huarte, Sonia, Xue, Ally L., Jones, Lyndon, Willcox, Mark D.P., Wolffsohn, James S.
Format: Article
Language:English
Subjects:
Aqueous deficiency
Artificial tear supplement
Dry eye disease
Evaporative dry eye
Lipomimetic
Meibomian gland dysfunction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear supplements in managing dry eye disease (DED). Ninety-nine participants fulfilling the TFOS DEWS II diagnostic criteria for DED (64% females; mean ± SD age, 44 ± 16 years) were enrolled in a prospective, multicentre, double-masked, parallel group, randomised controlled trial. Participants instilled lipid-based nanoemulsion drops or non-lipid-based aqueous drops for six months, at least four times daily. Symptomology, tear film and ocular surface characteristics were assessed at Days 0, 30, 60, 90, 120, 150 and 180. Sustained reductions in OSDI, DEQ-5, and SANDE symptom scores from baseline were observed from Day 30 onwards in both groups (all p 
ISSN:1542-0124
1937-5913
DOI:10.1016/j.jtos.2020.12.006